Videos

Martin Dreyling, MD, discusses how the safety and efficacy results from the TRIANGLE study in mantle cell lymphoma differ from prior expectations.

A panelist discusses updates from from the phase 2 study of loncastuximab + rituximab from ASH 2024.

Panelists discuss real-world evidence on dose escalation of luspatercept in lower-risk myelodysplastic syndrome (LR-MDS) (Patel et al, EHA 2024), highlighting its clinical benefits in improving patient outcomes, and share insights from the MAXILUS trial (Della Porta et al, EHA 2024), considering how this dosing strategy could influence clinical practice and enhance patient care.

A panelist discusses how molecular testing results, including ESR1 mutations, PIK3CA alterations, and other genomic findings, directly inform treatment decisions and sequencing of therapies for patients with MBC.

Hope S. Rugo, MD, FASCO, discusses how circulating tumor DNA testing enables real-time monitoring of disease progression, detection of emerging mutations, and assessment of treatment response in patients with MBC.

Panelists discuss dosing strategies for frontline luspatercept in lower-risk myelodysplastic syndrome, emphasizing individualized approaches to optimize efficacy and minimize adverse effects based on patient response and clinical factors.

Luis E. Raez, MD, discusses when minimal residual disease testing can be performed as an option for patients with lung cancer.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.

Panelists discuss how intravenous immunoglobulin (IVIG) therapy may reduce infection risk in patients with multiple myeloma who are receiving teclistamab treatment.

Panelists discuss how minimal residual disease assessment demonstrates superior depth of response with ciltacabtagene autoleucel compared with standard of care in patients who have lenalidomide-refractory multiple myeloma and received 1 to 3 prior therapies.

Panelists discuss how adding a fourth drug (daratumumab) to standard triplet induction therapy may improve outcomes for patients with newly diagnosed, transplant-eligible multiple myeloma.

Panelists discuss how the AQUILA trial evaluated whether daratumumab monotherapy provides superior outcomes compared with active monitoring in high-risk smoldering multiple myeloma patients.

Saeed Sadeghi, MD, discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome.

A panelist discusses how a new phase 2 study investigating the combination of loncastuximab tesirine plus rituximab in patients with relapsed/refractory follicular lymphoma aims to build upon earlier promising results by evaluating efficacy, safety, and durability of response in a larger patient population.

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients with fibrolamellar carcinoma.

Josep Maria Ribera, MD, PhD, discusses the current standard treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia and the rationale behind them.

Ghassan K. Abou-Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR inhibitors in the SUMMIT trial.

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with rituximab for R/R FL based on its complementary mechanism of action targeting CD19-expressing B -cells, demonstrated single-agent activity in early studies, and preliminary evidence suggesting potential synergy with anti-CD20 therapy in this setting.

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.

Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed multiple myeloma patient, considering factors such as age, comorbidities, and available therapeutic options to develop an optimal care plan.

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, distinguishing functional high-risk patients from those with standard risk, and tailoring treatment strategies accordingly.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk myelodysplastic syndromes (LR-MDS), demonstrated the long-term clinical value of luspatercept in improving hemoglobin levels and reducing transfusion dependence, with updated efficacy results presented by Garcia-Manero et al at ASH 2024.

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient performance status, and comorbidities while weighing the pros and cons of current options—such as chemotherapy-sparing regimens, androgen receptor pathway inhibitor (ARPI) selection, and the use of triplet versus doublet combination therapies—to optimize efficacy and minimize adverse effects based on each patient’s unique clinical profile.

James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or androgen receptor pathway inhibitors (ARPIs) such as abiraterone or enzalutamide, with the choice of frontline treatment depending on factors such as disease burden and patient characteristics, while also considering the structural and physical differences between these ARPIs, which may influence their efficacy and adverse effect profiles.

A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine therapy is crucial for detecting ESR1 mutations and other resistance mechanisms that can inform subsequent treatment selection.

Panelists discuss how mutational burden influences the duration of response to frontline luspatercept in lower-risk myelodysplastic syndrome (LR-MDS), as observed in the COMMANDS trial (Komrokji et al, EHA 2024), and when luspatercept should be chosen as a first-line treatment, considering its use before or alongside transfusion; they also explore the impact of luspatercept on hemoglobin levels and quality of life (Oliva et al, EHA 2024; Santini et al, ASH 2024), and the key factors in selecting between available treatment options for initial anemia management.